Phase I/II dose-escalation trial of RGX-111 for the treatment of mucopolysaccharidosis type I

Trial Profile

Phase I/II dose-escalation trial of RGX-111 for the treatment of mucopolysaccharidosis type I

Planning
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs RGX 111 (Primary)
  • Indications Mucopolysaccharidosis I
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 08 Nov 2017 According to a REGENXBIO media release, site activation is underway to support recruitment and patient enrollment, with the first patient expected to be dosed in the first half of 2018.
    • 06 Jan 2017 According to a REGENXBIO media release, the company expects to begin enrollment in the study in the second half of 2017.
    • 05 Jul 2016 According to Regenxbio media release, company expects to submit an IND of RGX-111 in the U.S. and Canada in the first half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top